Featured Content

Winston Wong, PharmD
President, W-Squared Group

The Punishing Cost of Cancer Care

(New York Times/Well blog) Dec 11, 2014 - As the price of chemotherapy now routinely reaches $100,000 for a full treatment course, my patients are forced more and more into making the equivalent of Sophie’s Choice when it comes to treating their cancer.

Commentary: This is becoming all too common a story. Even if ACA out-of-pocket caps apply, the maximum is still too high for...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

AstraZeneca First-in-class Ovarian Cancer Drug Wins EU Approval

(Reuters) Dec 18, 2014 - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.
read article »

Merck Acquires OncoEthix for Up to $375 Million

(Wall Street Journal) Dec 18, 2014 - Merck & Co. acquired privately held OncoEthix for up to $375 million, its latest push into the oncology market as the pharmaceutical giant continues bolstering its research-and-development pipeline.
read article (paid subscription required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Congress Fails to Act on Medicare Physician Payment Reform, SGR Repeal (ASCO in Action)

As long as necessary medical services are provided there is no political will and no economic reason to repeal...posted by: Clyde M. Jones

The Punishing Cost of Cancer Care (New York Times/Well blog)

This is becoming all too common a story. Even if ACA out-of-pocket caps apply, the maximum is still too high for...posted by: Winston Wong, PharmD

Mayo Clinic Physicians Say High-definition Scopes Accurately Assess Polyps, Costly Pathological Examinations May Not Be Necessary (Mayo Clinic)

So which will cost more...the HD evaluation or the pathologist.posted by: Winston Wong, PharmD

NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (Reuters)

These are results that payers need to note. Payers are asking for studies like this, documenting that the results...posted by: Winston Wong, PharmD

340B: Serving Vulnerable Patients or Enriching Hospitals? (Medscape Medical News)

This is has been a concern for many years. We know 340B pricing existing in our contracted institutional facilities,...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


NCCN has posted 1 new job.


Bayer Biopharmaceuticals, Inc. has posted 20 jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
TLOG +17.44%
AGEN +17.16%
MGNX +15.66%
BDSI -6.45%
TGTX -4.38%
BIND -4.36%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: January 3, 2015
Company: AstraZeneca PLC
Product: Lynparza™ (olaparib)

Date: Wed., January 7, 2015
Company: Sandoz Inc.
Product: EP2006

Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

See All OBR Radar items»